Target Name: CD207
NCBI ID: G50489
Other Name(s): CLC4K_HUMAN | OTTHUMP00000203299 | CD207 molecule, langerin | C-type lectin domain family 4 member K | CD207 molecule | Langerin | C-type lectin domain family 4, member K | CD207 antigen, langerin | Langerhans cell specific c-type lectin | CLEC4K

CD207: A Carbohydrate Antigen with Potential as A Drug Target

CD207, also known as CCL4K and HUMAN CD207, is a type of carbohydrate antigen 1 (CAIg) that is expressed in various tissues of the human body, including the lungs, heart, liver, and nervous system. It is a glycoprotein with a molecular weight of approximately 180 kDa and a monomeric structure composed of five constant and one variable region.

CD207 is involved in various physiological processes in the body, including cell adhesion, migration, and invasion. It is a critical receptor for many different types of cancer, including lung, breast, and ovarian cancer. CD207 has also been identified as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CD207 is overexpressed in many types of cancer, which has led to its potential as a drug target. For example, studies have shown that high levels of CD207 are associated with poor prognosis in patients with various types of cancer, including breast, lung, and ovarian cancer. Additionally, CD207 has been shown to promote the growth and survival of cancer cells in cell culture and animal models.

One of the main advantages of CD207 as a drug target is its expression in various tissues and its monomeric structure, which allows it to interact with other proteins in a more complex manner than its individual components. This is important because CD207 functions as a receptor for a wide range of molecules, including antibodies, cytokines, and drugs.

CD207 has also been shown to play a role in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that CD207 is overexpressed in the brains of individuals with these conditions and that targeting CD207 with drugs can lead to improvements in symptoms and quality of life.

In addition to its potential role in neurodegenerative diseases, CD207 has also been shown to be a potential drug target for other conditions, including cancer and autoimmune disorders. For example, studies have shown that CD207 is overexpressed in various types of cancer and that targeting CD207 with drugs can lead to improvements in cancer outcomes. Additionally, CD207 has been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, and has been shown to contribute to the development and progression of these conditions.

CD207 has also been shown to be involved in several cellular processes that are important for normal tissue growth and development. For example, studies have shown that CD207 is involved in cell division, cell migration, and the formation of tissues such as blood vessels and bones. Additionally, CD207 has been shown to play a role in the regulation of cellular signaling pathways, including the T cell receptor signaling pathway.

In conclusion, CD207 is a carbohydrate antigen that is expressed in various tissues of the human body and has been shown to be involved in various physiological processes in the body. Its monomeric structure and its ability to interact with other proteins make it a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of CD207 in these conditions and to develop effective treatments.

Protein Name: CD207 Molecule

Functions: Calcium-dependent lectin displaying mannose-binding specificity. Induces the formation of Birbeck granules (BGs); is a potent regulator of membrane superimposition and zippering. Binds to sulfated as well as mannosylated glycans, keratan sulfate (KS) and beta-glucans. Facilitates uptake of antigens and is involved in the routing and/or processing of antigen for presentation to T cells. Major receptor on primary Langerhans cells for Candida species, Saccharomyces species, and Malassezia furfur. Protects against human immunodeficiency virus-1 (HIV-1) infection. Binds to high-mannose structures present on the envelope glycoprotein which is followed by subsequent targeting of the virus to the Birbeck granules leading to its rapid degradation

More Common Targets

CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40